Evaluation of the Efficacy and Safety of Preoperative Camrelizumab Combined with Chemotherapy in Stage Ⅱ～Ⅲ Oesophageal Squamous Cell Carcinoma
Objective To assess the therapeutic efficacy and safety of the preoperative camrelizumab combined with chemotherapy for stage Ⅱ to Ⅲ oesophageal squamous cell carcinoma(ESCC).Methods The clinical data of forty resectable ESCC patients was retrospectively analyzed.All the patients received preoperative camrelizumab with chemotherapy(PCCT).6 weeks after preoperative therapy,the patients underwent surgery.Evaluation of tumor response was performed according to Re-sponse Evaluation Criteria in Solid Tumors 1.1(RECIST 1.1)and the pathological Tumor Volume Index(TVI).The adverse re-sponse was evaluated and monitored during the treatment.Results All the patients have received 2 or 3 cycles of PCCT success-fully.10 of them achieved complete response(CR),21 of them achieved partial response(PR),and 8 of them achieved stabiliza-tion of disease.The objective response rate was 77.5%,and the disease control rate(DCR)was 97.5%.The value of TVI was sig-nificantly lower after neoadjuvant therapy.4 patients(10.0%)had adverse events of grade 3 or 4.R0 resections were achieved in all patients who underwent surgery.Conclusion PCCT is an effective and tolerable treatment for resectable ESCC.
NETL
NSTL
万方数据
